sur Applied DNA Sciences, Inc.
Applied DNA Repositions TR8 PGx Test Post-FDA Announcement
Applied DNA Sciences, Inc. announced a strategic shift for its pharmacogenomics testing service, TR8™ PGx. The company now offers specific subpanels alongside full panel testing. This change aims to address genetic variants of the DPYD gene linked to deficiencies in metabolizing fluoropyrimidine drugs like capecitabine and fluorouracil, both critical in cancer therapies.
This move comes after the FDA's warning about potential toxicity in patients with certain DPYD variants. Applied DNA's TR8 PGx test, approved by New York State, helps identify individuals at risk. The company targets enhancing its service's adoption, specifically in oncology, cardiology, and psychiatry, to better guide clinical decisions and improve patient outcomes.
Dr. James A. Hayward, CEO of Applied DNA, emphasized the importance of genetic testing in treatment decisions. The TR8 PGx test offers insights into how patients might respond to various drugs, potentially enhancing treatment efficacy and safety.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Applied DNA Sciences, Inc.